Stock Monitor: Bio-Techne Post Earnings Reporting

LONDON, UK / ACCESSWIRE / February 14, 2018 / Active-Investors.com has just released a free research report on AVEO Pharma, Inc. (NASDAQ: AVEO). If you want access to this report all you need to do is sign up now by clicking the following link www.active-investors.com/registration-sg/?symbol=AVEO as the Company's latest news hit the wire. On February 12, 2018, the Cambridge based biopharmaceutical Company announced that the United Kingdom's National Institute for Health and Care Excellence (NICE) has recommended FOTIVDA® (tivozanib) for the first line treatment of adult patients with advanced renal cell carcinoma (aRCC). Register today and get access to over 1,000 Free Research Reports by joining our site below:

www.active-investors.com/registration-sg

Active-Investors.com is currently working on the research report for Bio-Techne Corporation (NASDAQ: TECH), which also belongs to the Healthcare sector as the Company AVEO Pharma. Do not miss out and become a member today for free to access this upcoming report at:

www.active-investors.com/registration-sg/?symbol=TECH

Active-Investors.com is focused on giving you timely information and the inside line on companies that matter to you. This morning, AVEO Pharma most recent news is on our radar and our team decided to put out a fantastic report on the company that is now available for free below:

www.active-investors.com/registration-sg/?symbol=AVEO

The positive recommendation triggers a $2 million milestone payment to AVEO from EUSA Pharma, a specialty pharmaceutical company with a focus on oncology and oncology supportive care and the licensee for tivozanib in Europe, North and South Africa, Latin America, and Australasia.

Recommendation Marks the First European Union Reimbursement Approval for FOTIVDA®

Michael Bailey, President and Chief Executive Officer of AVEO, stated that the recommendation from NICE marks the first European Union reimbursement approval for FOTIVDA®, helping ensure broadening patient access to FOTIVDA® in key European markets following its launch in Germany in the fall of 2017. This recommendation underscores the strength and commercial-stage value of our partnership with EUSA Pharma and triggers a $2 million milestone payment to AVEO.

Michael added that the Company looks forward to several potential additional key milestones in 2018, including further EU reimbursement decisions as well as topline data in the second quarter from our Phase-3 TIVO-3 study.

EC Approved Tivozanib for Treatment of Advanced RCC in 2017

In August 2017, the European Commission (EC) approved tivozanib in the European Union plus Norway and Iceland for the treatment of adult patients with advanced RCC and for adult patients who are vascular endothelial growth factor receptor (VEGFR) and mTOR pathway inhibitor-naïve following disease progression after one prior treatment with cytokine therapy for aRCC.1. The decision was primarily based on data from a global, open-label, randomized, multi-center Phase-3 trial (TIVO-1) which evaluated the efficacy and tolerability of tivozanib compared to a currently available comparator VEGFR-TKI treatment (sorafenib) in 517 patients with advanced RCC.

AVEO and EUSA Pharma Licensing Agreement for Tivozanib in Europe

In December 2015, AVEO and EUSA Pharma signed an exclusive license agreement, pursuant to which AVEO granted EUSA Pharma European rights to tivozanib for the treatment of advanced RCC. The agreement also included a number of additional territories outside North America, including South America and South Africa, and additional potential indications. Under the terms of the agreement, EUSA Pharma agreed to pay AVEO up to $386 million in future research and development (R&D) funding and milestone payments, assuming successful achievement of specified development, regulatory and commercialization objectives, as well as a tiered royalty ranging from a low double-digit up to mid-twenty percent on net sales of tivozanib in the agreement's territories. 30% of milestone and royalty payments received by AVEO, excluding research and development funding, are due to Kyowa Hakko Kirin (KHK) as a sublicensing fee in Europe. In the United States, the royalty obligation to KHK ranges from the low- to mid-teens on net sales.

About Advanced Renal Cell Carcinoma (aRCC)

Renal cell cancer is a disease in which malignant (cancer) cells form in tubules of the kidney. Smoking and misuse of certain pain medicines can affect the risk of renal cell cancer. Signs of renal cell cancer include blood in the urine and a lump in the abdomen. Advanced renal cell cancer occurs when cancer cells in the kidneys spread to other parts of the body and formed tumors in other places, and there is no one cause for this cancer.

About FOTIVDA® (tivozanib)

Tivozanib, AVEO's lead candidate, is an oral, once-daily, potent and highly-selective vascular endothelial growth factor receptor tyrosine kinase inhibitor (VEGFR-TKI), specifically designed for the treatment of adult patients with advanced RCC. Tivozanib has been investigated in several tumors types, including renal cell, colorectal and breast cancers. Tivozanib has been shown to significantly reduce regulatory T-cell production in preclinical models, enabling potentially enhanced activity when used in combination with immune modulating therapy.

About AVEO Pharmaceuticals, Inc.

Founded in 2001 and headquartered in Cambridge, Massachusetts, AVEO Oncology is a biopharmaceutical company dedicated to advancing a broad portfolio of targeted therapeutics for oncology and other areas of unmet medical need. The Company is focused on seeking to develop and commercialize its lead candidate tivozanib in North America as a treatment for renal cell carcinoma.

Stock Performance Snapshot

February 13, 2018 - At Tuesday's closing bell, AVEO Pharma's stock was slightly down 0.34%, ending the trading session at $2.96.

Volume traded for the day: 928.68 thousand shares.

Stock performance in the past twelve-month period ? up 361.71%; and year-to-date - up 6.09%

After yesterday's close, AVEO Pharma's market cap was at $350.17 million.

The stock is part of the Healthcare sector, categorized under the Biotechnology industry. This sector was up 0.1% at the end of the session.

Active-Investors:

Active-Investors (A-I) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and Canadian stocks. A-I has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.

A-I has not been compensated; directly or indirectly; for producing or publishing this document.

PRESS RELEASE PROCEDURES:

The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third-party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email info@active-investors.com. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by A-I. A-I is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.

NO WARRANTY

A-I, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. A-I, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, A-I, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

NOT AN OFFERING

This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither A-I nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit http://active-investors.com/legal-disclaimer/.

CONTACT

For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:

Email: info@active-investors.com

Phone number: 73 29 92 6381

Office Address: 6, Jalan Kia Peng, Kuala Lumpur, 50450 Kuala Lumpur, Wilayah Persekutuan Kuala Lumpur, Malaysia

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: Active-Investors